- Investing.com
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Metrics to compare | PROK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPROKPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.5x | −3.3x | −0.5x | |
PEG Ratio | −1.48 | −0.32 | 0.00 | |
Price/Book | −0.7x | 9.1x | 2.6x | |
Price / LTM Sales | 909.8x | 7.7x | 3.1x | |
Upside (Analyst Target) | 155.6% | 69.4% | 54.6% | |
Fair Value Upside | Unlock | 15.3% | 7.6% | Unlock |